We hypothesized that the unique radiofluorinated MUC1-conjugated folic acid (FA) hybrid peptide targeting both the MUC1 and folate receptors would be superior in breast cancer targeting to the radiofluorinated MUC1 monomeric peptide or folate targeting only the folate or folate receptors. This evidence concerns the gene MUC1 and breast cancer.